Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Abbott Labs Announces CE Mark For Testosterone Test - Quick Facts

RELATED NEWS
Trade ABT now with 

Abbott Laboratories (ABT: Quote) announced CE Marking or Conformite Europeenne for a testosterone assay with improved sensitivity and clinical utility. The company noted that ARCHITECT 2nd Generation Testosterone Assay can accurately measure the wide range of testosterone levels seen in a number of different patient populations and clinical settings.

Testosterone assays play an important role in the diagnosis and management of many medical conditions in men, women, and children.

The company stated that the new assay runs on its fully-automated ARCHITECT family of analyzers and is available in several European countries, Asia Pacific, Latin America, Japan, Africa, Middle East, and India, pending country registration.

The ARCHITECT 2nd Generation Testosterone Assay is a chemiluminescent microparticle immunoassay for the quantitative determination of testosterone in human serum and plasma.

Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Social networking giant Facebook, Inc. said Wednesday after the markets closed that its second quarter profit more than doubled from last year, as revenue surged 61% amid strong growth in mobile advertising. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue. With traders reacting to the latest batch of earnings news, stocks fluctuated over the course of the trading day on Wednesday before eventually ending the session mixed. The Dow ended the day in the red, but the broader Nasdaq and S&P 500 managed to close in positive territory. House Republicans revealed a series of recommendations to address the crisis along the U.S.-Mexico border on Wednesday, although party differences may prevent a final bill from being passed before the August recess.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.